#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Clinical Osteology / 2021 - 4

Osteoporosis care during the COVID-19 pandemic

Download PDF Czech version

Authors: Rosa Jan
Authors‘ workplace: Osteocentrum Affidea Praha, s. r. o.
Published in: Clinical Osteology 2021; 26(4): 186-190
Category:

Overview

COVID-19 is an emerging infectious disease that has specific characteristics that interfere with the care of patients with osteoporosis. This article discusses the interfaces between osteological issues and COVID-19. A prevalent fracture very modestly increases the risk of death from COVID-19 but in hospitalized patients, the prevalence of vertebral fracture can be considered another aspect of polymorbidity increasing the likelihood of an adverse course of infection. Vitamin D deficiency correlates with worse outcomes in COVID-19, and sufficient vitamin D saturation is very likely protective in relation to COVID-19. Containment measures at the peak of the pandemic may result in muscle loss and increased risk of falls in the elderly. Densitometry and majority of laboratory tests can be easily delayed in patients with osteoporosis. This also applies to parenteral administration of bisphosphonates, whereas continuation of oral bisphosphonate therapy can be ensured by electronic prescription. Teriparatide should not be discontinued for more than 2–3 months, and the interval between denosumab administrations should not exceed 7 months.

Keywords:

bisphosphonates – denosumab – fractures – COVID-19 – osteoporosis

Sources
  1. Berlin DA, Gulick RM, Martinez FJ. Severe COVID-19. NEJM 2020; 383(25): 2451–2460. Dostupné z  DOI: <http://dx.doi.org/10.1056/NEJMcp2009575A>.
  2. Cantini F, Goletti D, Petrone L. Immune therapy, or antiviral therapy, or both for COVID-19: a systematic review. Drugs 2020; 80(18): 1929–1946. Dostupné z DOI: <https://doi.org/10.1007/s40265–020–01421-w>.
  3. Formenti AM, Pedone E, di Filippo L et al. Are women with osteoporosis treated with denosumab at risk of severe COVID-19? Endocrine 2020; 70(2): 203–205. Dostupné z  DOI: <hhtp://dx.doi.org/10.1007/s12020–020–02500–4>.
  4. Cleverley J, Piper J, Jones MM. The role of chest radiography in confirming COVID -19 pneumonia. BMJ 2020; 370:m2426. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.m2426>
  5. WHO Coronavirus (COVID-19) Dashboard. Dostupné z  WWW: <https://covid19.who.int/>.
  6. Český statistický úřad. Počet zemřelých (aktualizace týdenních časových řad) – časové řady. Dostupné z WWW: <https://www.czso. cz/csu/czso/obypz_cr>.
  7. Yoneda T, Mundy GR. Monocytes regulate osteoclast-activating factor production by releasing prostaglandins. J Exp Med 1979; 150(2): 338–350. Dostupné z  DOI: <http://dx.doi.org/10.1084/ jem.150.2.338>.
  8. Salvio G, Gianfelice C, Firmani F et al. Bone metabolism in SARS- -CoV-2  disease: possible osteoimmunology and gender implications. Clin Rev Bone Mineral Metabol 2020; 18(1–7): 51–57. Dostupné z DOI: <https://doi.org/10.1007/s12018–020–09274–3>.
  9. Obitsu S, Ahmed N, Nishitsuji H et al. Potential enhancement of osteoclastogenesis by severe acute respiratory syndrome coronavirus 3a/X1 protein. Arch Virol 2009; 154: 1457–1464. Dostupné z DOI: <https://doi.org/10.1007/s00705–009–0472-z>.
  10. Garnero P, Thompson E, Woodworth T et al. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6  receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthr Rheum 2010; 62(1): 33–43. Dostupné z  DOI: <http:// dx.doi.org/10.1002/art.25053>.
  11. Clift AK, Coupland CA, Keogh RH et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ 2020; 371: m3731. Dostupné z DOI: <http://dx.doi.org/10.1136/ bmj.m3731>.
  12. Center RC, Nguyen TV, Schneider D et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353(9156): 878–882. Dostupné z  DOI: <http:// dx.doi.org/10.1016/S0140–6736(98)09075–8>.
  13. di Filippo L, Formenti AM, Doga M  et al. Radiological Thoracic Vertebral Fractures are Highly Prevalent in COVID-19 and Predict Disease Outcomes. J Clin Endocrinol Metab 2021; 106: e602-e614. Dostupné z DOI: <http:// doi: 10.1210/clinem/dgaa738>.
  14. Daneshkah A, Agrawal V, Eshein A  et al. The possible role of vitamin D  in supressing cytokine storm and associated mortality in COVID-19  patients. Dostupné z  DOI: <https://doi.org/10.1101/2020.0 4.08.20058578>.
  15. Kunutsor SK, Apekey TA, Steur M. Vitamin D and risk of future hypertension: meta-analysis of 283,537  participants. Eur J  Epidemiol 2013; 28(3): 205–221. Dostupné z  DOI: <http://dx.doi.org/10.1007/ s10654–013–9790–2>.
  16. Mauss D, Jarczok MN, Hoffmann K et al. Associations of vitamin D  levels with type 2  diabetes in older working adults. Int J  Med Sci 2015; 12(5): 362–368. Dostupné z  DOI: <http://dx.doi.org/10.7150/ ijms.10540>.
  17. Yao Y, Zhu L, He L  et al. A  meta-analysis of the relationship between vitamin D deficiency and obesity. Int J Clin Exp Med 2015; 8(9): 14977–14984.
  18. Herrick KA, Storandt RJ, Afful J et al. Vitamin D status in the United States. Am J Clin Nutr 2019; 110(1): 150–157. Dostupné z DOI: <http:// dx.doi.org/10.1093/ajcn/nqz037>.
  19. Colotta F, Jansson B, Bonelli F. Modulation of imflammatory and immune responses by vitamin D. J Autoimmun 2017; 85: 78–97. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaut.2017.07.007>.
  20. Jain A, Chaurasia R, Sengar NS et al. Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers. Sci Rep 2020; 10(1): 20191. Dostupné z DOI: <https://doi.org/10.1038/s41598–020–77093-z>
  21. Ben-Eltriki M, Hopefl R, Wright JM et al. Association between vitamin D status and risk of developing severe COVID-19 infection: a meta-analysis of observational studies. J Am Coll Nutr 2021; 1–11. Dostupné z DOI: <http://dx.doi.org/10.1080/07315724.2021.1951891>.
  22. Vimaleswaran KS, Forouhi NG, Khunti K. Vitamin D  and COVID19. BMJ 2021; 372: n544. Dostupné z DOI: <http://dx.doi.org/10.1136/ bmj.n544>.
  23. Kirwan R, McCullough D, Butler T et al. Sarcopenia during COVID19  lockdown restrictions: long-term health effects of short-term muscle loss. Geroscience 2020; 42(6): 1547–1578. Dostupné z  DOI: <http://dx.doi.org/10.1007/s11357–020–00272–3>.
  24. The International Society for Clinical Densitometry. COVID-19 Statements. Statement March 30, 2020. Dostupné z WWW: <https://iscd. org/knowledge-base/march-30–2020-statement/>.
  25. The American Society for Bone and Mineral Research. Joint Guidance on Osteoporosis Management in the Era of COVID-19 from the ASBMR, AACE, Endocrine Society, ERCTS & NOF. Dostupné z WWW: <https://www.asbmr.org/about/statement-detail/joint-guidance-on- -osteoporosis-management-covid-19>
  26. Yu W, Tsourdi E, Clarke BL et al. Osteoporosis management in the era of COVID-19. J Bone Mineral Res 2020; 35(6): 1009–1013. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.4049>.
  27. Paskins Z, Crawford-Manning F, Bullock L  et al. Identifying and managing osteoporosis before and after COVID-19: rise of the remote consultations? Osteoporos Int 2020; 31(9): 1629–1632. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–020–05465–2>.
  28. Blanch-Rubió J, Soldevila-Domenech N, Tío L  et al. Influence of anti-osteoporosis treatments on the incidence of COVID-19  in patients with non-inflammatory rheumatic conditions. Aging 2020; 12(20): 19923–19937. Dostupné z  DOI: <http://dx.doi.org/10.18632/ aging.104117>.
  29. Tsourdi E, Zillikens MC, Meier C et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS.. J Clin Endocrinol Metab 2021; 106: 264–281. Dostupné z DOI: <http://doi:10.1210/clinem/dgaa756>.
  30. Hauser B, Alonso N, Riches PL. Review of current real-world experience with teriparatide as treatment of osteoporosis in different patient groups. J Clin Med 2021; 10(7): 1403. Dostupné z DOI: <https://doi. org/10.3390/jcm10071403>
  31. The American Society for Bone and Mineral Research. Joint Guidance on Osteoporosis Management in the Era of COVID-19 from the ASBMR, AACE, Endocrine Society, ERCTS & NOF. Dostupné z WWW: <https://www.asbmr.org/about/statement-detail/joint-guidance-on- -osteoporosis-management-covid-19>.
  32. Hamspon G, Stone M, Lindsay JR et al. Diagnosis and Management of Osteoporosis during COVID-19: Systematic Review and Practical Guidance. Calcif Tissue Int 2021; 109(4): 351–362. Dostupné z DOI: <https://doi.org/10.1007/s00223–021–00858–9>
  33. Ma Q, Hao ZW, Wang YF. The effect of estrogen in coronavirus disease 2019 Am J Physiol Lung Cell Mol Physiol 2021; 321(1): L219-L227. Dostupné z DOI: <http://dx.doi.org/10.1152/ajplung.00332.2020>.
  34. Kocijan R, Behanova M, Reichardt B et al. Poor adherence to parenteral osteoporosis therapies during COVID-19 pandemic. Arch Osteoporos 2021; 16(1): 46. Dostupné z DOI: <http://dx.doi.org/10.1007/ s11657–021–00904-x>.
  35. European Alliance of Associations for Rheumatology. EULAR View-points on SARS-CoV-2  vaccination in patients with RMDs. Dostupné z  WWW: <https://www.eular.org/eular_sars_cov_2_vaccination_rmd_patients.cfm>
  36. Siegel  CA, Melmed GY, McGovern DPB et  al. SARS-Cov-2  vaccination for patients with imflammatory bowel diseases: recommendations from an international consensus meeting. Gut 2021; 70(4): 635–640. Dostupné z  DOI: http://dx.doi.org/10.1136/gutjnl-2020– 324000>.
  37. Benucci M, Infantino M, Marotto D et al. Vaccination against SARS- -CoV-2 in patients with rheumatic diseases: doubts and perspectives. Clin Experimental Rheumatol 2021; 39(1): 196–202.
Labels
Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics General practitioner for adults Radiodiagnostics Rehabilitation Rheumatology Traumatology Osteology
Atypical femoral fractures – what´s new?
Bone mineral content, subcutaneous and visceral adipose tissue volumetric measurements: A pilot study in routine computed tomography examinations
Latest research and news in osteology
Supplementing of the Abstract Book: XXIVth Congress of Czech and Slovak Osteologists
Article was published in

Clinical Osteology

Issue 4
2021 Issue 4
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#